早洩治疗市场－全球产业规模、份额、趋势、机会及预测（依药物类型、剂型、剂型、通路、地区及竞争格局划分，2021-2031年）

全球早洩治疗市场预计将从 2025 年的 29.5 亿美元成长到 2031 年的 46.4 亿美元，复合年增长率为 7.84%。

该市场涵盖药物疗法，例如选择性血清素再回收抑制剂（SSRIs）和局部麻醉剂，以及旨在延长射精潜伏期和提高性满意度的行为疗法。推动这一成长的关键因素包括全球性功能障碍盛行率的上升，以及围绕男性健康的污名化现象逐渐减少​​的文化转变，这鼓励了更多人寻求医疗咨询。此外，在现有医疗保健系统中，处方药和非处方药的可近性不断提高，也为该产业的扩张奠定了坚实的基础。

然而，由于法规环境严格，市场面临许多障碍。许多有效的口服治疗药物缺乏特定核准，尤其是在美国等关键地区，迫使患者依赖仿单标示外用药。这种监管空白阻碍了新产品的商业化，并限制了患者获得标准化治疗方案的机会。根据欧洲泌尿系统协会预测，到2024年，早洩将成为最常见的男性性功能障碍，全球自述盛行率估计在20%至30%之间，凸显了对核准治疗性介入的迫切需求。

市场驱动因素

远端医疗和数位健康平台的普及正在成为全球早洩治疗市场的主要驱动力，从根本上改变了患者获取和使用医疗保健的方式。这些数位化解决方案提供私密的远端咨询和直接面向消费者的药物配送服务，克服了患者难以启齿的尴尬，避免了传统泌尿系统就诊常常伴随的耻辱感。这种转变促使许多以前不愿寻求治疗的男性更积极参与治疗，从而显着提高了性健康服务的使用率。根据Hims & Hers Health公司于2024年11月发布的“2024年第三季度财务业绩报告”，该公司用户群（主要为个性化性健康产品用户）已增至200万，同比增长44%。

同时，创新局部麻醉剂和非处方药物的引入，透过提供有效且按需的替代方案，重新定义了护理标准，取代了全身性用药。製造商正致力于开发使用者友善、非侵入性的产品形式，例如擦拭巾、喷雾剂和穿戴式技术，与口服选择性血清素再回收抑制剂(SSRI) 相比，这些产品副作用较少。 「in2」设备就是这项创新的杰出代表。根据 Virility Medical 公司 2024 年 5 月发布的公告“Virility Medical 推出 in2 设备”，这项非药物疗法的临床试验表明，射精控制能力最多可提高 4.7 倍。大型製药企业的成功案例也印证了该领域的巨大商业性潜力。例如，Recodati 公司报告称，其泌尿系统和泌尿系统肿瘤科部门在 2024 年实现了 42.6% 的显着同比增长，这证实了市场对有效男性健康解决方案的需求日益增长。

市场挑战

严格的法规环境是全球早洩治疗市场扩张的主要障碍，因为它阻碍了某些疗法的顺利商业化。在美国等主要市场，由于达泊西汀等标靶治疗尚未获得美国食品药物管理局(FDA) 的核准，医疗服务提供者不得不依赖处方抗忧郁症进行仿单标示外治疗。这种依赖性给医生带来了法律责任风险，并导致报销政策不一致，从而增加了患者的自付费用，并降低了患者长期坚持治疗的动机。这些复杂的监管问题使得获利前景不明朗，製药公司也因此不愿投资新药候选药物的昂贵临床试验。

广泛的患者需求与监管机构为药物核准制定的严格临床定义之间的脱节，进一步加剧了这项挑战。根据欧洲泌尿系统的数据，如果采用严格的临床标准，到2024年，早洩的终生盛行率估计约为男性人口的2-3%。这种狭隘的分类限制了认证核可药的官方市场，与寻求帮助的更广泛患者群体形成鲜明对比。这最终限制了新型标准化治疗方法的获利能力。

市场趋势

人们越来越倾向于个人化、多模式的治疗方案，从标准化的单一疗法转向个别化客製化的治疗计划，显着改善了治疗效果。与仿单标示外学名药用药不同，这些客製化方案通常会结合行为调整和复杂的特定剂量，以优化药物控制并减轻副作用。这一趋势在领先的数位医疗服务提供者的策略中尤为明显，他们正致力于研发独特的双效配方，以同时针对早洩的生理和心理因素。这种策略转变带来了显着的财务效益。根据 Hims & Hers Health, Inc. 于 2025 年 11 月发布的“2025 年第三季财务业绩报告”，其销售额达到 5.99 亿美元，年增 49%。这一显着成长主要归功于个人化医疗服务的广泛应用。

同时，穿戴式神经调节装置的兴起正在开启一个全新的治疗领域，专注于控制射精反射的神经路径。与仅能麻痹感觉的局部麻醉剂不同，这些非侵入性设备利用经皮电刺激来调节神经活动，为药物治疗无效的患者提供了一种无需药物的选择。这项创新同时获得了监管部门的核准和投资者的支持，标誌着治疗领域正朝着高科技、解剖学解决方案的方向发展。正如2025年2月《星论坛报》的报导「明尼苏达州开发的早洩贴片获得FDA批准」所报道，Morari Medical公司已成功资金筹措320万美元用于其创新型神经调节贴片的商业化，这凸显了市场对基于设备的治疗方法的强劲需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球早洩治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依药物类型（达泊西汀、5型磷酸二酯酶（PDE5）抑制剂、选择性血清素再回收抑制剂、局部麻醉剂、泽坦）
  • 依类型（口服疗法、局部疗法）
  • 按剂型（锭剂、喷雾剂）
  • 按通路（医院、网路药局、零售药局）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美早洩治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲早洩治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区早洩治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲早洩治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲早洩治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球早洩治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Absorption Pharmaceuticals Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Premature Ejaculation Treatment Market is projected to expand from USD 2.95 Billion in 2025 to USD 4.64 Billion by 2031, registering a compound annual growth rate of 7.84%. This market encompasses pharmacotherapeutic interventions, such as selective serotonin reuptake inhibitors and topical anesthetics, as well as behavioral therapies aimed at prolonging ejaculation latency and enhancing sexual satisfaction. Key factors propelling this growth include the rising prevalence of sexual dysfunction worldwide and a cultural shift toward reducing the stigma associated with male health, which encourages more individuals to seek medical advice. Furthermore, the growing accessibility of both prescription and over-the-counter treatments across established healthcare systems establishes a solid base for industry expansion.

Nevertheless, the market encounters significant obstacles due to a strict regulatory environment, particularly in major regions like the United States where many effective oral treatments lack specific approval, leading to a reliance on off-label prescribing. This regulatory void creates hurdles for the commercialization of new products and restricts patient access to standardized care pathways. According to the European Association of Urology, in 2024, premature ejaculation was recognized as the most frequent male sexual dysfunction, with self-reported prevalence rates estimated between 20% and 30% globally, highlighting the urgent requirement for approved therapeutic interventions.

Market Driver

The proliferation of telemedicine and digital health platforms acts as a major catalyst for the Global Premature Ejaculation Treatment Market by fundamentally transforming how patients access and engage with care. These digital solutions overcome the significant hurdle of embarrassment by providing discreet, remote consultations and direct-to-consumer medication delivery, thereby circumventing the stigma frequently linked to traditional in-person urology appointments. This shift has engaged a large demographic of men who were previously hesitant to seek treatment, resulting in a marked uptake of sexual health services. According to Hims & Hers Health, Inc., in their 'Third Quarter 2024 Financial Results' from November 2024, the company's subscriber base-which largely utilizes personalized sexual health products-expanded to 2.0 million, signifying a 44% year-over-year increase.

In parallel, the introduction of innovative topical anesthetics and over-the-counter products is redefining treatment standards by offering effective, on-demand alternatives to systemic medications. Manufacturers are increasingly focusing on user-friendly, non-invasive forms such as wipes, sprays, and wearable technology that reduce side effects relative to oral selective serotonin reuptake inhibitors. A notable instance of such innovation is the "in2" device; as stated by Virility Medical in their May 2024 announcement regarding the 'Virility Medical Launches in2 Device', clinical trials for this drug-free option showed up to a 4.7-fold improvement in ejaculation control. The wider commercial potential of this sector is further demonstrated by the success of major pharmaceutical players; for instance, Recordati reported that their urology and uro-oncology division saw a significant 42.6% growth in 2024 compared to the prior year, underscoring the strong and growing demand for effective male health solutions.

Market Challenge

A rigorous regulatory environment poses a major obstacle to the expansion of the Global Premature Ejaculation Treatment Market by hindering the smooth commercialization of specific therapeutic agents. In key markets such as the United States, the absence of Food and Drug Administration approval for targeted treatments like dapoxetine forces healthcare providers to depend on off-label antidepressant prescriptions. This reliance generates liability risks for physicians and leads to inconsistent insurance reimbursement policies, which raises out-of-pocket costs for patients and discourages long-term medical adherence. As a result, pharmaceutical firms are deterred from funding costly clinical trials for new drug candidates, as the route to profitability is obscured by these regulatory complications.

This difficulty is further exacerbated by the gap between widespread patient demand and the stringent clinical definitions mandated by regulatory authorities for drug approval. According to the European Association of Urology, in 2024, the prevalence of the lifelong subtype of premature ejaculation was determined to be roughly 2% to 3% of the male population when subjected to strict clinical criteria. This narrow classification restricts the officially recognized market for approved medications, standing in sharp contrast to the broader population seeking assistance, which ultimately limits the revenue potential for new, standardized therapies.

Market Trends

There is a growing preference for personalized combination therapies, which is significantly enhancing treatment efficacy by moving away from standardized monotherapies toward tailored regimens. Unlike generic off-label prescriptions, these customized solutions frequently integrate pharmacotherapy with behavioral adjustments or compound specific dosages to optimize control while mitigating side effects. This trend is particularly prominent in the strategies of major digital health providers, who are shifting toward proprietary, dual-action formulations that target both the physiological and psychological components of premature ejaculation. This strategic pivot is generating substantial financial outcomes; according to Hims & Hers Health, Inc., in their 'Third Quarter 2025 Financial Results' from November 2025, revenue hit $599 million, representing a 49% year-over-year rise driven largely by the uptake of these personalized health services.

At the same time, the rise of wearable neuromodulation devices is creating a new therapeutic class that focuses on the neural pathways controlling the ejaculatory reflex. Differing from topical anesthetics that merely numb sensation, these non-invasive devices employ transcutaneous electrical stimulation to modulate nerve activity, providing a drug-free option for patients who do not respond to pharmaceutical treatments. This innovation has secured both regulatory validation and investor support, indicating a shift toward high-tech, anatomical solutions. As reported by the Star Tribune in the February 2025 article 'Minnesota-invented patch for premature ejaculation gains FDA clearance', Morari Medical secured $3.2 million to back the commercial release of its innovative neuromodulation patch, highlighting the market's strong demand for device-based interventions.

Key Market Players

• Absorption Pharmaceuticals Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Innovus Pharmaceuticals Inc.
• Merck & Co., Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd

Report Scope

In this report, the Global Premature Ejaculation Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Premature Ejaculation Treatment Market, By Drug Type

• Dapoxetine
• Phosphodiesterase Type 5 (PDE5) Inhibitors
• Selective Serotonin Reuptake Inhibitors
• Topical Anesthetics
• Zertane

Premature Ejaculation Treatment Market, By Type

• Oral Therapies
• Topical Therapies

Premature Ejaculation Treatment Market, By Dosage Form

• Pills
• Spray

Premature Ejaculation Treatment Market, By Distribution Channel

• Hospitals
• Online Pharmacies
• Retail Pharmacies

Premature Ejaculation Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Premature Ejaculation Treatment Market.

Available Customizations:

Global Premature Ejaculation Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Premature Ejaculation Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Dapoxetine, Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake Inhibitors, Topical Anesthetics, Zertane)
  • 5.2.2. By Type (Oral Therapies, Topical Therapies)
  • 5.2.3. By Dosage Form (Pills, Spray)
  • 5.2.4. By Distribution Channel (Hospitals, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Premature Ejaculation Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Type
  • 6.2.3. By Dosage Form
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Premature Ejaculation Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Dosage Form
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Premature Ejaculation Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Dosage Form
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Premature Ejaculation Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Dosage Form
      • 6.3.3.2.4. By Distribution Channel

7. Europe Premature Ejaculation Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Type
  • 7.2.3. By Dosage Form
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Premature Ejaculation Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Dosage Form
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Premature Ejaculation Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Dosage Form
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Premature Ejaculation Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Dosage Form
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Premature Ejaculation Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Dosage Form
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Premature Ejaculation Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Dosage Form
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Premature Ejaculation Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Type
  • 8.2.3. By Dosage Form
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Premature Ejaculation Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Dosage Form
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Premature Ejaculation Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Dosage Form
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Premature Ejaculation Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Dosage Form
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Premature Ejaculation Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Dosage Form
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Premature Ejaculation Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Dosage Form
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Premature Ejaculation Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Type
  • 9.2.3. By Dosage Form
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Premature Ejaculation Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Dosage Form
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Premature Ejaculation Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Dosage Form
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Premature Ejaculation Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Dosage Form
      • 9.3.3.2.4. By Distribution Channel

10. South America Premature Ejaculation Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Type
  • 10.2.3. By Dosage Form
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Premature Ejaculation Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Dosage Form
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Premature Ejaculation Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Dosage Form
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Premature Ejaculation Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Dosage Form
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Premature Ejaculation Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Absorption Pharmaceuticals Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Allergan PLC
• 15.3. AstraZeneca PLC
• 15.4. Bayer AG
• 15.5. Eli Lilly and Company
• 15.6. GlaxoSmithKline PLC
• 15.7. Innovus Pharmaceuticals Inc.
• 15.8. Merck & Co., Inc.
• 15.9. Pfizer, Inc.
• 15.10. Teva Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer